

# Hans Nissbrandt

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11101574/hans-nissbrandt-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

1,857  
citations

24  
h-index

29  
g-index

29  
ext. papers

2,025  
ext. citations

4.6  
avg, IF

4.33  
L-index

#	Paper	IF	Citations
29	The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 4812-20	6.6	246
28	L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. <i>Journal of Neurochemistry</i> , <b>2010</b> , 112, 1465-76	6	206
27	Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. <i>Brain</i> , <b>2014</b> , 137, 1998-2014	11.2	139
26	Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2011</b> , 42, 327-40	7.5	121
25	GABAB-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. <i>Synapse</i> , <b>1993</b> , 15, 229-38	2.4	89
24	Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. <i>BMC Medical Genetics</i> , <b>2010</b> , 11, 36	2.1	86
23	GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. <i>Psychoneuroendocrinology</i> , <b>2016</b> , 65, 54-66	5	72
22	Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 153-61	8.7	64
21	Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. <i>Brain Research</i> , <b>2003</b> , 973, 81-91	3.7	62
20	Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease <b>2005</b> , 133B, 88-92		60
19	Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. <i>Synapse</i> , <b>1994</b> , 17, 217-24	2.4	58
18	PITX3 polymorphism is associated with early onset Parkinson's disease. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 114-7	5.6	57
17	Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease - a multicenter study. <i>BMC Medical Genetics</i> , <b>2014</b> , 15, 131	2.1	55
16	Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. <i>Physiology and Behavior</i> , <b>2014</b> , 136, 135-44	3.5	52
15	Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. <i>Neuropsychopharmacology</i> , <b>1999</b> , 20, 287-96	8.7	52
14	Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. <i>European Journal of Neuroscience</i> , <b>2006</b> , 24, 617-24	3.5	51
13	Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by gamma-hydroxybutyric acid (GABA) are specifically induced by activation of GABA(B) receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1998</b> , 357, 611-9	3.4	50

12	Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight. <i>Diabetes</i> , <b>2017</b> , 66, 1062-1073	0.9	48
11	The Stomach-Derived Hormone Ghrelin Increases Impulsive Behavior. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 1199-209	8.7	45
10	Influence of ghrelin on the central serotonergic signaling system in mice. <i>Neuropharmacology</i> , <b>2014</b> , 79, 498-505	5.5	45
9	gamma-Hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1993</b> , 348, 491-7	3.4	40
8	Noisy galvanic vestibular stimulation promotes GABA release in the substantia nigra and improves locomotion in hemiparkinsonian rats. <i>PLoS ONE</i> , <b>2012</b> , 7, e29308	3.7	40
7	The influence of serotonergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1992</b> , 346, 12-9	3.4	31
6	Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 195-202	1.7	30
5	3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. <i>Journal of Neurochemistry</i> , <b>1997</b> , 69, 1684-92	6	19
4	Inhibition of dopamine re-uptake: significance for nigral dopamine neuron activity. <i>Synapse</i> , <b>1997</b> , 25, 215-26	2.4	16
3	Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors. <i>Experimental Neurology</i> , <b>2010</b> , 221, 251-9	5.7	9
2	Kinesin light chain 1 gene haplotypes in three conformational diseases. <i>NeuroMolecular Medicine</i> , <b>2010</b> , 12, 229-36	4.6	8
1	Dopamine Release in Substantia Nigra: Release Mechanisms and Physiological Function in Motor Control <b>2005</b> , 85-99		6